Tempus AI, Inc. (NASDAQ:TEM) Given Average Rating of “Hold” by Brokerages

Tempus AI, Inc. (NASDAQ:TEM) has been assigned an average recommendation of “Hold” from the seventeen analysts that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have given a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $65.6923.

TEM has been the topic of several research reports. BTIG Research upped their price target on shares of Tempus AI from $70.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Lake Street Capital cut shares of Tempus AI to a “hold” rating in a research note on Monday, July 20th. Weiss Ratings raised shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 12th. TD Cowen restated a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Finally, Stifel Nicolaus decreased their target price on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating on the stock in a research report on Monday, August 3rd.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: The company received FDA clearance for an ECG-based tool designed to flag pulmonary hypertension. The clearance expands Tempus AI’s clinical technology offerings and supports its strategy of applying artificial intelligence to healthcare diagnostics. Tempus AI Wins FDA Clearance for ECG Tool
• Positive Sentiment: Tempus AI also benefited from a read-through from Moderna and Merck’s positive Phase 3 melanoma results for personalized cancer therapy V940 combined with Keytruda. Personalis, which Tempus acquired for approximately $1.5 billion, supported the trial, potentially validating the strategic value of that acquisition and its role in precision oncology. Detailed trial data are still pending. Tempus AI and Moderna’s Melanoma Results
• Neutral Sentiment: Tempus AI’s latest reported quarter showed revenue growth of 21.6% year over year to $382.5 million and a smaller-than-expected loss, providing fundamental support for the recent rebound. However, the company remains unprofitable, and analysts’ average rating is “Hold” with a consensus price target of $65.69.
• Negative Sentiment: CEO Eric Lefkofsky sold 250,000 shares for roughly $17.1 million in two transactions, reducing his direct ownership by about two-thirds. CEO Ryan Fukushima also sold 14,286 shares worth approximately $1 million. The transactions were made under pre-arranged Rule 10b5-1 plans, which reduces their value as a signal of management’s current outlook but nevertheless adds selling pressure. SEC Insider Sale Filing
• Negative Sentiment: Cathie Wood’s investment firm reportedly sold approximately $4 million of Tempus AI shares, adding to concerns about profit-taking after the stock’s sharp recovery.

Insiders Place Their Bets

In other Tempus AI news, EVP Andrew Polovin sold 7,927 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $56.00, for a total transaction of $443,912.00. Following the transaction, the executive vice president owned 138,140 shares in the company, valued at $7,735,840. This trade represents a 5.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 14,286 shares of Tempus AI stock in a transaction on Friday, August 21st. The shares were sold at an average price of $70.00, for a total value of $1,000,020.00. Following the completion of the transaction, the chief executive officer directly owned 47,420 shares of the company’s stock, valued at $3,319,400. This represents a 23.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,041,238 shares of company stock valued at $56,768,767 in the last quarter. Company insiders own 24.26% of the company’s stock.

Institutional Trading of Tempus AI

A number of institutional investors have recently modified their holdings of the stock. JPL Wealth Management LLC bought a new position in shares of Tempus AI in the third quarter worth $26,000. Los Angeles Capital Management LLC acquired a new position in Tempus AI in the fourth quarter valued at about $27,000. EMC Capital Management acquired a new position in Tempus AI in the second quarter valued at about $29,000. Harvest Fund Management Co. Ltd bought a new stake in Tempus AI during the third quarter worth about $38,000. Finally, Whittier Trust Co. lifted its position in Tempus AI by 190.0% during the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock worth $41,000 after purchasing an additional 570 shares during the period. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Stock Performance

Shares of NASDAQ TEM opened at $70.69 on Friday. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The stock’s fifty day moving average price is $54.37 and its two-hundred day moving average price is $51.71. Tempus AI has a one year low of $40.77 and a one year high of $104.32. The firm has a market cap of $12.75 billion, a price-to-earnings ratio of -49.09 and a beta of 3.58.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The firm had revenue of $382.49 million for the quarter, compared to analysts’ expectations of $379.69 million. The company’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same quarter last year, the business earned ($0.22) EPS. On average, equities analysts forecast that Tempus AI will post -1.38 EPS for the current year.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.